Perrigo Bolsters US Generics Ahead Of Separation Plans
Signed Eighth Agreement With Sol-Gel To Further Expand Partnership
Perrigo has expanded its agreement with Sol-Gel Technologies to cover ten products, shortly after warning that plans to separate the firm’s Prescription Pharmaceuticals US generics unit “in the short term” would likely “destroy shareholder value.”
You may also be interested in...
Collaboration partners Perrigo and Sol-Gel Technologies face legal action stemming from Perrigo’s filing of an ANDA for generic Duobrii lotion for the treatment of plaque psoriasis in adults.
Perrigo management provided colorful commentary on Perrigo’s latest endeavors to separate the company’s US generics business, following the recent sale of Perrigo’s Rosemont Pharmaceuticals subsidiary for an “attractive” multiple.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.